Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GnuBio: Whole Genome Sequencing for $30

This article was originally published in Start Up

Executive Summary

Say goodbye to the $1000 genome, and even the $100 genome. Thanks to a fledging start-up out of Harvard, there may be an even lower near-term benchmark. Speaking at a meeting in Boston, GnuBio described technology for doing whole-genome sequencing for as little as $30 a pop using an interation of microdroplet technology already in commercial use, out of the same lab.

You may also be interested in...



The How And When Of Applying Sequencing To Clinical Diagnostics

Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing. As technology innovation continues, costs decrease, and the pace and scope of clinical genomic studies picks up, the notion of sequencing as the foundation for a clinical diagnostics platform is gaining more support. Delivering value to diagnostics customers ultimately may demand that instrument providers move downstream, involving themselves in data analysis and workflow and even test development, to prime the clinical market.

The How And When Of Applying Sequencing To Clinical Diagnostics

Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing. As technology innovation continues, costs decrease, and the pace and scope of clinical genomic studies picks up, the notion of sequencing as the foundation for a clinical diagnostics platform is gaining more support. Delivering value to diagnostics customers ultimately may demand that instrument providers move downstream, involving themselves in data analysis and workflow and even test development, to prime the clinical market.

Illumina Goes Consumer

Microarray and sequencing specialist Illumina has entered the consumer genomics game with a DTC personal genome sequencing service. It's distancing itself from regulators by partnering with others to handle any secondary data interpretation and dialog with customers, but cautious or not, by reaching out directly to the public, the move does turn on its head the traditional notion of first developing a technology tool for research, then moving on to more regimented clinical applications.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel